06 Mar 2025
// PR NEWSWIRE
02 May 2024
// PRESS RELEASE
09 Apr 2024
// PRESS RELEASE
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
About
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
CORPORATE CONTENT #SupplierSpotlight
06 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/lindus-health-and-tiefenbacher-group-launching-clinical-trial-to-advance-mecfs-research-and-treatment-302393805.html
02 May 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/05/02/tiefenbacher-group-renovation-of-headquarters-in-hamburg/
09 Apr 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/04/09/tiefenbacher-first-to-market-launch-rivaroxaban/
08 Apr 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/04/08/tiefenbacher-group-welcomes-new-coo-sandip-tarate/
19 Mar 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/03/19/tiefenbacher-group-awarded-ecovadis-silver-medal/
29 Feb 2024
// PRESS RELEASE
https://tiefenbacher-pharmaceuticals.com/2024/02/29/tiefenbacher-group-on-awareness-for-rare-disease-day/
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Hematology Brand Name: Xarelto-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Hematology Brand Name: Xarelto-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 16, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2023
Details:
Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Neurology Brand Name: Aubagio-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2023
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Product Name : Aubagio-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Details:
Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.
Lead Product(s): Bilastine
Therapeutic Area: Immunology Brand Name: Bilastine Tiefenbacher
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2023
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.
Product Name : Bilastine Tiefenbacher
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2023
Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2022
Lead Product(s) : Abiraterone Acetate,Prednisolone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 17, 2022
Details:
Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Apixaban Tiefenbacher
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2022
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Product Name : Apixaban Tiefenbacher
Product Type : HPAPI
Upfront Cash : Inapplicable
October 20, 2022
Details:
Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.
Lead Product(s): Vildagliptin,Metformin
Therapeutic Area: Endocrinology Brand Name: Vildagliptin-Metformin-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2022
Lead Product(s) : Vildagliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.
Product Name : Vildagliptin-Metformin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2022
Details:
Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Lead Product(s): Rivaroxaban
Therapeutic Area: Hematology Brand Name: Xarelto-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 15, 2022
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2022
Details:
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Lead Product(s): Lacosamide
Therapeutic Area: Neurology Brand Name: Lacosamide-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2022
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Product Name : Lacosamide-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 22, 2022
Details:
Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Lead Product(s): Apremilast
Therapeutic Area: Dermatology Brand Name: Otezla-Generic
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2022
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Product Name : Otezla-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
January 12, 2022
Inspections and registrations
ABOUT THIS PAGE